2 ex­per­i­men­tal Ebola vac­cines show prom­ise

Chronicle (Zimbabwe) - - Worldwide -

MI­AMI — Two ex­per­i­men­tal vac­cines against the Ebola virus have shown prom­ise in pro­tect­ing against the haem­or­rhagic fever for at least a year, ac­cord­ing to the re­sults of a ma­jor clin­i­cal trial pub­lished on Wed­nes­day.

The re­port in the New Eng­land Jour­nal of Medicine is the first full ac­count of a large-scale ef­fort to test what could be the first vac­cine against Ebola.

The out­break of the highly con­ta­gious and of­ten deadly virus killed more than 11 000 peo­ple, mainly in Liberia, Guinea and Sierra Leone, as it swept West Africa from late 2013 to 2016. The phase II study in­volved 1 500 peo­ple in Monrovia, Liberia. Par­tic­i­pants were ran­domly as­signed to re­ceive one of two vac­cines be­ing tested, or a placebo.

The vac­cine can­di­dates in­cluded the fron­trun­ner, rVSV-ZEBOV, ini­tially en­gi­neered by Cana­dian govern­ment sci­en­tists and now li­censed to Merck, Sharp and Dohme Cor­po­ra­tion.

The sec­ond vac­cine can­di­date was cAd3-EBOZ, co-de­vel­oped by the US Na­tional In­sti­tute for Al­lergy and In­fec­tious Dis­eases’ (NIAID) Vac­cine Re­search Cen­tre and Glax­o­SmithK­line.

Af­ter one month, 84 per­cent of rVSV-ZEBOV re­cip­i­ents de­vel­oped an an­ti­body re­sponse. At one year, 80 per­cent still had this pro­tec­tion.

For the other can­di­date, cAd3-EBOZ, 71per­cent de­vel­oped an an­ti­body re­sponse, and 64 per­cent still had such a re­sponse at one year, when the trial ended. “This clin­i­cal trial has yielded valu­able in­for­ma­tion that is es­sen­tial for the con­tin­ued de­vel­op­ment of th­ese two Ebola vac­cine can­di­dates and also demon­strates that well-de­signed, eth­i­cally sound clin­i­cal re­search can be con­ducted dur­ing an epi­demic,” said NIAID di­rec­tor An­thony Fauci. — Al Jazeera

Newspapers in English

Newspapers from Zimbabwe

© PressReader. All rights reserved.